A week after posting an all-time stock high, Intuitive Surgical (NSDQ:ISRG) is poised to bedazzle Wall Street for the 12th straight quarter tomorrow.
MAKO Surgical Corp.
St. Jude Medical rebounds after “Greek tragedy” | Wall Street Beat
Shares of St. Jude Medical (NYSE:STJ) clawed back some of the value lost yesterday in what 1 waggish analyst termed a “Greek tragedy.”
STJ shares closed down 3.3% yesterday at $39.96 when the company revealed a $56 million writedown after a Greek distributor failed to pay up for an estimated 2 years worth of sales.
Mako Surgical meets The Street, shares slip
Mako Surgical (NSDQ:MAKO) met Wall Street’s forecasts for its 4th-quarter and full-year financial numbers, but MAKO shares are sliding on The Street this morning after opening near their 52-week high.
The Ft. Lauderdale-based robotic surgery system maker reported losses of $5.6 million, or 14 cents per share, on sales of $32.9 million for the 3 months ended Dec. 31, 2011, amounting to a 122.5% addition to the top line and a 43.1% reduction in net losses, compared with the same period in 2010.
“Exit hangover” casts a pall on private equity | Wall Street Beat
Private equity players are in for some stiff competition this year, as large-cap PE shops invade the middle-market space, according to a report from PE stalwart Bain & Co.
The company’s Global PE Report details a huge “exit overhang” – more aptly deemed an “exit hangover” by PE Hub’s Jonathan Marino – as PE-backed companies seek exits.
And the mega-deals of the past 10 years or so are a thing of the past, according the report, as detailed by Marino.
Will Advanced BioHealing pay off for Shire with a buyout deal? | Wall Street Beat
Buyout chatter pushed shares of Shire plc (FTSE:SHP) up nearly 2% in London yesterday and added 1.4% on Wall Street.
Mako Surgical names new regulatory VP | Personnel Moves
Mako Surgical (NSDQ:MAKO) tapped Lawrence Gibbons to replace its regulatory affairs vice president, James Keller, who resigned effective Feb. 3.
Gibbons, 60, was most recently with Fisher & Paykel Healthcare (NZE:FPH), where he helped establish a manufacturing facility in Mexico and set up the quality system at the company’s New Zealand headquarters.
Goldman pans Wall Street’s med-tech estimates
Wall Street’s overall take on sales and earnings forecasts for medical device makers this year is too high, according to Goldman Sachs (NYSE:GS) analyst David Roman, who sees The Street’s 4th-quarter top-line estimates as split evenly among companies with upside and downside.
Mako Surgical boosts Q3 sales, losses still widen | Earnings Roundup
Shares of Mako Surgical (NSDQ:MAKO) are down 6.6 percent since the robotic surgery firm reported wider third-quarter losses, despite a nearly 67 percent increase in sales.
Mako reported losses of $9.7 million, or 24 cents per share, on sales of $20.0 million during the three months ended Sept. 30.
Mako Surgical boosts Q3 sales, losses still widen
Shares of Mako Surgical (NSDQ:MAKO) are down 6.6 percent since the robotic surgery firm reported wider third-quarter losses, despite a nearly 67 percent increase in sales.
Mako reported losses of $9.7 million, or 24 cents per share, on sales of $20.0 million during the three months ended Sept. 30.
Medical device investment rose during Q2, even as deal volume fell | Wall Street Beat
Medical device investment deals got fatter and less frequent during the second quarter, as the value of deals grew 9 percent but their number slid 17 percent, according to PricewaterhouseCoopers.
Backers pumped $841 million into med-tech firms with 90 deals during the three months ended June 30, according to the consulting firm’s MoneyTree report. That’s up 26 percent and 3 percent, respectively, over the first quarter. The industry’s share of the venture capital cash spend on life sciences last quarter ticked down to 40 percent, however, compared with Q1 numbers.
BSX’s CEO, Bard’s bids for Clearstream, Infuse’s lawsuits , AdvCellTech’s stem cell trail, NuVasive’s spat, BSX’s narrow escape and Mako’s Wall Street love made headlines this week | MassDevice.com +7
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.